Exelixis, Inc.s (NASDAQ:EXEL) Financials Are Too Obscure To Link With Current Share Price Momentum: Whats In Store For the Stock?
Exelixis (NASDAQ:EXEL) has had a great run on the share market with its stock up by a significant 5.1% over…
21,120€
-0,47%
Echtzeit-Aktienkurs Exelixis
Bid:
Ask:
Nachrichten zur Exelixis Aktie
Exelixis director Garber Alan M sells shares worth over $460k By Investing.com
Exelixis director Garber Alan M sells shares worth over $460k…
Exelixis expects 2023 revenue of ~$1.83B
…
Exelixis, Inc. 2023 Q3 - Results - Earnings Call Presentation
…
Exelixis reports positive results for Cabometyx in treating neuroendocrine tumors
…
Exelixis started at buy at Wainwright on targeted oncology pipeline
…
Exelixis (EXEL) Late-Stage Study in Pancreatic Tumors Positive
Exelixis (EXEL) phase III CABINET study shows dramatic improvement in efficacy in advanced pancreatic neuroendocrine tumors and advanced extra-pancreatic neuroendocrine…
Exelixis reports positive results for Cabometyx in pancreatic cancer
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Exelixis appoints Amy Peterson as Chief Medical Officer
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Exelixis appoints Amy Peteson as Chief Medical Officer
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 8-K EXELIXIS, INC. For: Aug 23
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Exelixis stock price raised to $29 vs. $25 at Oppenheimer
Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...…
Exelixis lead product hits main goal in Phase 3 prostate cancer trial
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Exelixis, Ipsen Say Prostate Cancer Phase 3 Trial Met One of Two Main Goals
Exelixis, Ipsen Say Prostate Cancer Phase 3 Trial Met One of Two Main Goals...…
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
– Cabozantinib in combination with atezolizumab demonstrated a statistically significant reduction in the risk of disease progression or death compared…
Surging Earnings Estimates Signal Upside for Exelixis (EXEL) Stock
Exelixis (EXEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings…
Insiderhandel: EVP and CFO verkauft Aktien von Exelixis im Wert von 1.230.600$
Senner, Christopher J. - Vorstand - Tag der Transaktion: 2023-08-03...…
Insiderhandel: EVP and CFO verkauft Aktien von Exelixis im Wert von 1.240.800$
Senner, Christopher J. - Vorstand - Tag der Transaktion: 2023-08-04...…
Insiderhandel: EVP, Commercial verkauft Aktien von Exelixis im Wert von 631.531$
Haley, Patrick J. - Vorstand - Tag der Transaktion: 2023-08-03...…
Insiderhandel: EVP, General Counsel & Sec verkauft Aktien von Exelixis im Wert von 1.093.587$
Hessekiel, Jeffrey - Vorstand - Tag der Transaktion: 2023-08-01...…
Exelixis (EXEL) Q2 Earnings Top, Cabometyx Drives Growth
Exelixis (EXEL) beats second-quarter 2023 earnings and sales estimates as Cabometyx drives growth in approved indications....…
Exelixis (EXEL) Q2 2023 Earnings Call Transcript
EXEL earnings call for the period ending June 30, 2023....…
Exelixis (EXEL) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for Exelixis (EXEL) give insight into how the company performed in the quarter ended June 2023, but…
Exelixis (EXEL) Tops Q2 Earnings and Revenue Estimates
Exelixis (EXEL) delivered earnings and revenue surprises of 40.91% and 4.74%, respectively, for the quarter ended June 2023. Do the…
Form 10-Q EXELIXIS, INC. For: Jun 30
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Exelixis (EXEL) Reports Next Week: What You Should Expect
Exelixis (EXEL) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming…
Form 8-K EXELIXIS, INC. For: Jul 18
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Exelixis, Teva settle patent dispute over cancer drug Cabometyx
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Why Is Exelixis (EXEL) Down 0.6% Since Last Earnings Report?
Exelixis (EXEL) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates for…
Form 8-K EXELIXIS, INC. For: May 31
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
2 Unstoppable Growth Stocks to Buy in 2023 and Beyond
Both Axsome Therapeutics and Exelixis have potentially game-changing products in their pipelines....…
Exelixis (EXEL) Q1 Earnings Miss, Revenues Increase Y/Y
Exelixis (EXEL) misses first quarter 2023 earnings and sales estimates, but product sales increase year over year....…
Exelixis a new overweight at Piper Sandler on Cabometyx, pipeline
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Exelixis (EXEL) Q1 2023 Earnings Call Transcript
EXEL earnings call for the period ending March 31, 2023....…
Compared to Estimates, Exelixis (EXEL) Q1 Earnings: A Look at Key Metrics
The headline numbers for Exelixis (EXEL) give insight into how the company performed in the quarter ended March 2023, but…
Form 8-K EXELIXIS, INC. For: May 07
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Exelixis, facing challenge from Farallon, says Willsey to exit board
...By Svea Herbst-Bayliss
BOSTON (Reuters) - Biotechnology company......…
Form 8-K EXELIXIS, INC. For: Apr 12
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Insiderhandel: EVP, General Counsel & Sec verkauft Aktien von Exelixis im Wert von 778.989$
Hessekiel, Jeffrey - Vorstand - Tag der Transaktion: 2023-04-05...…
Exelixis responds to Farallon Capital letter
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
J&J, C3.ai, Walmart, Exelixis, Conagra, and More Stock Market Movers
Johnson & Johnson proposes to pay at least $8.9 billion to settle claims that its talcum powder causes cancer, while…
Exelixis faces proxy battle with investor Farallon Capital - report
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Farallon to launch proxy fight at biotech Exelixis: WSJ
Hedge fund Farallon Capital Management plans to launch a proxy fight at cancer-drug maker Exelixis Inc. EXEL, and has nominated…
Farallon Capital to Wage Proxy Battle at Biotech Firm
Farallon has nominated three directors to the board of Exelixis, which develops cancer-fighting drugs....…
Argo Group, Brightcove See Activist Action
Activists file with the SEC on Argo Group International, Exelixis, Brightcove, and LivePerson...…
Form 8-K EXELIXIS, INC. For: Mar 16
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Exelixis Targeted as Activist Farallon Capital Partners Reveals 7.2% Holding
Activist investor Farallon Capital Partners has revealed a 7.2% stake in Exelixis....…
Why Exelixis Stock Leaped More Than 4% Higher Today
Oh, how some investors love stock buyback programs....…
Large Exelixis shareholder Farallon calls biotech undervalued, needs board refresh
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
First Republic, Athenex fall; Franchise Group, Exelixis rise
Stocks that traded heavily or had substantial price changes Monday: First Republic, Athenex fall; Franchise Group, Exelixis rise...…